TP53 and central nervous system cancer: IDH mutations are associated with MGMT promoter hypermethylation, TP53 mutation, 1p/19q codeletion, ATRX inactivation, younger age, and improved prognosis while being inversely correlated with EGFR amplification in glioma (Chou et al., 2010; Wiestler et al., 2013; Yan et al., 2009; Zou et al., 2013).